OKYO Pharma Limited (OKYO)
NASDAQ: OKYO · IEX Real-Time Price · USD
1.660
+0.080 (5.06%)
At close: Jul 19, 2024, 4:00 PM
1.650
-0.010 (-0.60%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Company Description
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom.
Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.
The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain.
The company was incorporated in 2007 and is headquartered in London, the United Kingdom.
OKYO Pharma Limited
| Country | United Kingdom |
| Founded | 2007 |
| IPO Date | May 17, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Dr. Gary S. Jacob Ph.D. |
Contact Details
Address: 55 Park Lane London, X0 W1K 1NA United Kingdom | |
| Phone | 44 (0) 207 495 2379 |
| Website | okyopharma.com |
Stock Details
| Ticker Symbol | OKYO |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| IPO Price | $4.00 |
| CIK Code | 0001849296 |
| CUSIP Number | 679345108 |
| ISIN Number | US6793451088 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Gary S. Jacob Ph.D. | Chief Executive Officer and Executive Director |
| Michael Paul Beck | Founder |
| Keeren Shah | Chief Financial Officer |
| Dr. William A. Clementi Ph.D., Pharm.D. | Chief Operating Officer |
| Dr. Rajkumar Patil Ph.D. | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 11, 2024 | 6-K | Report of foreign issuer |
| Jul 10, 2024 | 6-K | Report of foreign issuer |
| Jul 10, 2024 | 6-K | Report of foreign issuer |
| May 8, 2024 | 6-K | Report of foreign issuer |
| Apr 30, 2024 | 6-K | Report of foreign issuer |
| Apr 9, 2024 | 6-K | Report of foreign issuer |
| Apr 4, 2024 | 6-K | Report of foreign issuer |
| Apr 2, 2024 | 6-K | Report of foreign issuer |
| Mar 29, 2024 | 6-K | Report of foreign issuer |
| Mar 22, 2024 | 6-K | Report of foreign issuer |